Adsorption of anaphylatoxins from the plasma of systemic lupus erythematosus patients using dextran sulfate cellulose columns

Journal of Clinical Apheresis

Volumn 13, Issue 3, 1998, Pages 108-113

  Matsuki, Yasunori ^a   Suzuki, Kimihiro ^a   Kawakami, Makoto ^a   Ishizuka, Toshiaki ^a   Hidaka, Toshihiko ^a   Nakamura, Haruo ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

C3a; C4a; C5a; Immunoadsorption

Indexed keywords

ANAPHYLATOXIN; CELLULOSE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A; DEXTRAN SULFATE; NAFAMSTAT MESILATE;

ADULT; APHERESIS; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOADSORPTION; MALE; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR DISEASE;

ADULT; ANAPHYLATOXINS; CELLULOSE; DEXTRAN SULFATE; FEMALE; HUMANS; IMMUNOSORBENT TECHNIQUES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED;

EID: 0031734175     PISSN: 07332459     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1101(1998)13:3<108::AID-JCA3>3.0.CO;2-Z     Document Type: Article

References (28)

1. Goldstein IM: Complement: biologically active products. In Gallin JI, Goldstein IM, Synderman R (eds): "Inflammation: Basic Principles and Clinical Correlates." 2nd Ed. New York: Raven, 1992, p 63.
2. Hulgi TE: Structure and function of the anaphylatoxins. Springer Semin Immunopathol 7:193, 1984.
3. Shin HS, Synderman R, Friedman E, Mellors A, Mayer MM: Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement. Science 162:361, 1968.
4. Sacks T, Moldow CF, Craddock PR, Bowers TK, Jacob HS: Oxygen radicals mediate endothelial damage by complement-stimulated granulocytes: An in vitro model of immune vascular damage. J Clin Invest 61:1161, 1978.
5. Goldstein IM, Weissmann G: Generation of C5a-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes. J Immunol 113:1583, 1974.
6. Jose PJ, Forrest MJ, Williams TJ: Human C5a des Arg increases vascular permeability. J Immunol 127:2376-2380, 1981.
7. Montz H, Koch KC, Zierz R, Gotze O: The role of C5a in IL-6 production induced by lipopolysaccharide or EL-1. Immunology 74:373, 1991.
8. Belmont HM, Hopkins P, Edelson HS, Kaplan HB, Ludewig R, Weissmann G, Abramson S: Complement activity during systemic lupus erythematosus. Arthritis Rheum 29:1085-1089, 1986.
9. Wild G, Watkins J, Milford Ward A, Hughes P, Hume A, Rowell NR: C4a anaphylatoxin levels as an indicator of disease activity in systemic lupus erythematosus. Clin Exp Immunol 80:167-170, 1990.
10. Hopkins P, Belmont HM, Buyton J, Philips M, Weissmann G, Abramson SB: Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebriris. Arthritis Rheum 31:632-641, 1988.
11. Suzuki K, Hara M, Harigai M, Ishizuka T, Hirose T, Matsuki Y, Kawaguchi Y, Kitani A, Kawagoe M, Nakamura H: Continuous removal of anti-DNA antibody, using a new extracorporeal immunoadsorption system, in patients with systemic lupus erythematosus. Arthritis Rheum 34:1546-1552, 1991.
12. Matsuki Y, Suzuki K, Kawakami M, Ishizuka T, Kawaguchi Y, Hidaka T, Nakamura H: High avidity anti-DNA antibody removal from the serum of SLE patients by adsorption using dextran sulfate cellulose columns. J Clin Apheresis 11:30-35, 1996.
13. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277, 1982.
14. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Committee on prognosis studies in SLE: Derivation of the SLE-DAI. Arthritis Rheum 35:630-640, 1992.
15. Mizuno K, Tsujino M, Takada M, Hayashi M, Atsumi K: Studies on bredinin. I. Isolation, characterization and biological properties. J Antibiot 27:775-782, 1974.
16. Watkins J, Wild G, Smith S: Nafamostat to stable plasma samples taken for complement measurements. Lancet 1:896-897, 1989.
17. Issekutz AC, Movat KW and Movat HZ: Enhanced vascular permeability and haemorrhage-inducing activity of zymosanactivated plasma. Clin Exp Immunol 41:505-511, 1980.
18. Negoro N, Okumura M, Takeda T, Koda S, Amatsu K, Inoue T, Curd JG, Kanayama Y: The clinical significance of iC3b neoantigen expression in plasma from patients with systemic lupus erythematosus. Arthritis Rheum 32:1233-1242, 1989.
19. Senaldi G, Ireland R, Bellingham AJ, Vergani D, Veerapan K, Wang F: IgM reduction in systemic lupus erythematosus. Arthritis Rheum 31:1213, 1988.
20. Garwryl MA, Chudwin DS, Longlois PF, Lint TF: The terminal component complex, C5b-9, a marker of disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 31: 188-195, 1988.
21. Belmont HM, Buyon J, Giorno R, Abramson S: Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum 37:376-383, 1994.
22. Aotsuka S, Funahashi T, Tani N, Okawa-Takatsuji M, Kinoshita M, Yokohari R: Adsorption of anti-DNA antibodies by immobilized polyanionic compounds. Clin Exp Immunol 79:215-220, 1990.
23. Tridon A, Palcoux JB, Jouanel P, Bezou MJ, Coulet M, Betail G: Complement activation during low-density lipoprotein apheresis. Artif Organs 16:577-585, 1992.
24. Rinder CS, Rinder HM, Smith BR, Fitch JCK, Simth MJ, Tracey IB, Matis LA, Squinto SP, Rollins SA: Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 96: 1564-1572, 1995.
25. Suzuki Y, Uchida J, Tsuji, Kuzuhara K, Kara S, Nihei H, Ogura Y, Otsubo O, Mimura N: Acute change in C3a and C5a in an anaphylactoid reaction in hemodialysis patients. Tohoku J Exp Med 152:33-45, 1987.
26. Yamamoto A, Kojima S, Shiba-Harada M, Kawaguchi A, Hatanaka K: Assessment of the biocompatibility and long-term effect of LDL-apheresis by dextran sulfate-cellulose column. Artif Organs 16:177-181, 1992.
27. Craddock P, Fehr J, Dalmaso A, Brigham K, Jacob H: Hemodialysis leukopenia. J Clin Invest 59:879-888, 1977.
28. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin SW: Complement activation during cardiopulmonary bypass. N Engl J Med 304:497-505, 1981.